This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Momenta Pharmaceuticals' Management Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

Momenta Pharmaceuticals, Inc.(MNTA)

Bank of America Merrill Lynch 2012 Health Care Conference Call

May 16, 2012 8:00 pm ET


Richard P. Shea – Senior Vice President and Chief Financial Officer


Sumant S. Kulkarni – Bank America/Merrill Lynch


Sumant S. Kulkarni – Bank America/Merrill Lynch

Good afternoon everyone. I’m very pleased to have Momenta here with us today. Thanks for taking the time and sticking around for this last presentation it’s going to be an interesting one because this is a really interesting company in the generic pharmaceuticals space. For those of you who that don’t know me I’m Sumant Kulkarni and I’m part of the specialty pharmaceuticals in U.S. major pharmaceuticals team here at the firm. So we have Rick Shea, who is the CFO and who is back with us this year and Lora Pike, who is with us for the first time this year is the IR for Momenta. Thanks.

Richard P. Shea

Thanks very much Sumant. I will draw your attention to our risk factors particularly as included within our SEC filings. Momenta was founded and built based on analytical technologies for deconvolution and characterizing complex mixture drugs and these complex mixture drugs include polysaccharides heparin based drugs, polypeptides as well as biologics which includes glycosylated proteins and antibodies and technology that we use is by understanding the drug and understanding the chemical structure of the drug we are able to analyze and recreate exact copies of a complex drug in order to make a generic version or a biosimilar version. But we are also able to do structure activity relationship analysis and whether to understand how to engineer novel drugs based on this technology.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.83 0.20%
FB $118.57 0.00%
GOOG $698.21 0.00%
TSLA $238.90 -1.20%
YHOO $36.53 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs